ONC-392 is a new generation of anti-CTLA-4 monoclonal antibody developed by OncoC4 in the United States and Onco Immunity in China. Due to its unique pH sensitivity, ONC-392 does not cause lysosomal degradation of CTLA-4, enabling more efficient and selective removal of regulatory T cells (a major culprit in tumor immune escape) from the tumor microenvironment. Preclinical studies have demonstrated that the efficacy and safety of ONC-392 is greatly improved compared to CTLA-4 targeted drugs.

Previous research

The ONCOC4-sponsored PRESERVE-001 (ONC-392-001) clinical study is being conducted in more than 40 clinical facilities in the United States and Australia, with approximately 300 patients enrolled in monotherapy and combination therapy groups. China ONke Immunology has completed a dose escalation study of ONC-392 monotherapy for advanced solid tumors in 2022. Completed and ongoing clinical studies in China and the United States have shown that ONC-392 has a good safety profile, is well tolerated, and exhibits good antitumor effects.

Research opportunity

Clinical studies of ONC-392 monotherapy for the treatment of advanced/metastatic hepatocellular carcinoma, esophageal cancer, gastric cancer and anal canal cancer have been approved by the ethics committees of six clinical centers. If you or your relatives and friends have been diagnosed with hepatocellular carcinoma, esophageal cancer, gastric cancer, or anal canal cancer, and are able to perform light physical activity or office work after at least first-line and at most third-line systemic anti-tumor therapy, and are interested in participating in the study, please go to the following hospitals and let the study doctor determine whether you can participate in the study.

Medical Center/Principal investigator

Professor Xu Ruihua, Cancer Prevention Center, Sun Yat-sen University (Guangzhou).

Professor Liu Lian, Shandong University Qilu Hospital (Jinan).

Wuhan University People's Hospital Shouyi Hospital District (Wuhan) Professor Wu Long.

Professor Lin Rongbo, Fujian Cancer Hospital (Fuzhou).

The First Affiliated Hospital of Zhengzhou University (Zhengzhou) Professor Zong Hong.

Professor Yu Yiyi, Zhongshan Hospital Affiliated to Fudan University (Shanghai).

After the ethical approval of other research institutions is obtained, relevant information will be announced on the public account in a timely manner, so that you can participate in the project nearby.